Anjan K. Pradhan

Anjan K. Pradhan

Auto-generated profile, based on publicly available information

Anjan K. Pradhan

Department of Oncology Science, University of Oklahoma College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
APAnjan K. Pradhan
Anjan K. Pradhan
JMJinkal Modi
Jinkal Modi
SMSantanu Maji
Santanu Maji
AKAmit Kumar
Amit Kumar
PBPraveen Bhoopathi
Praveen Bhoopathi
Paul FisherPaul Fisher
Paul Fisher
Genome-wide gene expression analysis and animal modeling indicate that melanoma differentiation associated gene-9 (mda-9, Syntenin, Syndecan binding protein, referred to as MDA-9/Syntenin) positively regulates melanoma metastasis. The MDA-9/Syntenin protein contains two tandem PDZ domains serving as a nexus for interactions with multiple proteins that initiate transcription of metastasis-associated genes. Although targeting either PDZ domain abrogates signaling and prometastatic phenotypes, the integrity of both domains is critical for full biological function. Fragment-based drug discovery and NMR identified PDZ1i, an inhibitor of the PDZ1 domain that effectively blocks cancer invasion in vitro and in vivo in multiple experimental animal models. To maximize disruption of MDA-9/Syntenin signaling, an inhibitor has now been developed that simultaneously binds and blocks activity of both PDZ domains. PDZ1i was joined to the second PDZ binding peptide (TNYYFV) with a PEG linker, resulting in PDZ1i/2i (IVMT-Rx-3) that engages both PDZ domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression, culminating in repression of melanoma metastasis. The in vivo antimetastatic properties of IVMT-Rx-3 are enhanced when combined with an immune-checkpoint inhibitor. Collectively, our results support the feasibility of engineering MDA-9 dual-PDZ inhibitors with enhanced antimetastatic activities and applications of IVMT-Rx-3 for developing novel therapeutic strategies effectively targeting melanoma and in principle, a broad spectrum of human cancers that also overexpress MDA-9/Syntenin.

16 June 2026 in Cancer Research
Verified
Journal Article
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC. Significance: Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition. See related article by Delgado Herrera et al., p. XX .

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
ERK inhibition accelerated lipid turnover in pancreatic cancer cells.

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC.Significance:Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition.See related commentary by Delgado Herrera and Ferrer, p. 3374

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Cell growth and lipidomic changes upon ERK inhibition in combination with inhibition of fatty acid oxidation.

15 July 2026
Verified
Other
Open access
RAVI THAKURRAVI THAKUR
RAVI THAKUR
DWDi Wang
Di Wang
THTuo Hu
Tuo Hu
CHChunbo He
Chunbo He
JZJunzhang Zhao
Junzhang Zhao
PSPankaj Singh
Pankaj Singh
Blood biochemistry indices from the CFPAC-1 tumor-bearing mice treated with MEK inhibitor, ranolazine, or their combinations.